BenevolentAI Results Presentation Deck
2022 Financial highlights
Revenue
R&D - Drug discovery ("DD") ¹
R&D - Product & technology ["P&T"]¹
G&A - Business operations ["Bus Ops"]¹
Underlying expenses related to share-based payments
Other income
Normalised operating loss
Normalised EPS (in pence)²
Weighted average ordinary shares outstanding (in millions)
1) Excludes exceptional costs related to the Business
Combination
2) Normalised EPS also excludes taxation impact
from exceptional items and finance income related
to the Business Combination
31 December
2022
£'000
10,560
(43,179)
(21,914)
(16,500)
(23,731)
166
(94,598)
(72.6)
109.1
BenevolentAl Proprietary
2021
£'000
4,625
(27,129)
(19,963)
(13,944)
(51,390)
90
(107,711)
(104.6)
89.9
Revenue increase across
AstraZeneca collaboration, with 3
additional novel targets in chronic
kidney disease (x1) and idiopathic
pulmonary fibrosis (x2).
DD spend increase driven by
advancing pipeline into later stages
of development, particularly
BEN-2293 adaptive Phase I/II and
BEN-8744 CTA filing enablement in
Dec-22. Net 4 named programmes
added into pipeline during the year.
P&T spend increase reflecting
increased headcount, expected to
plateau.
Bus Ops spend +18%, driven
predominantly by listing status and
expected to maintain at this level.
Benevolent 10View entire presentation